Search

Displaying results 1071 - 1080 of 10000 in total
  1. Drug

    Cholecystokinin

    go.drugbank.com/drugs/DB08862
    ApprovedInvestigationalWithdrawn

    Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form. … This hormone has also been shown to have positive effects on enteric smooth muscle contraction and on nerve activity at multiple locations in the peripheral and central nervous system.

  2. Drug

    Foreskin keratinocyte (neonatal)

    go.drugbank.com/drugs/DB10772
    Approved

    The defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. … To construct a "living" alternative, a dermal substitute based on collagen I gel was created with mesenchymal cells such as fibroblasts.

  3. Drug

    Oxaprozin

    go.drugbank.com/drugs/DB00991
    Approved

    Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  4. Drug

    Imdevimab

    go.drugbank.com/drugs/DB15940
    ApprovedInvestigational

    [L39130,L39135] Full safety and efficacy data on imdevimab are not yet available, and further evaluation of this investigational therapy will continue.[L23529,L23539,L14303] … [A221495] On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older.

  5. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442).

  6. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442).

  7. Target

    TATA-box-binding protein

    go.drugbank.com/bio_entities/BE0012882
    TargetHumans

    TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:2194289, PubMed:2363050 … During assembly of the core PIC on the promoter, as part of TFIID, TBP binds to and also bends promoter DNA, irrespective of whether the promoter contains a TATA box (PubMed:33795473).

    Polypeptides: TATA-box-binding proteinSynonyms: TATA-box factor
  8. Drug

    Daptomycin

    go.drugbank.com/drugs/DB00080
    ApprovedInvestigational

    [A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal … [A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing

    Products: Daptomycin in Sodium Chloride
  9. Drug

    Aminolevulinic acid

    go.drugbank.com/drugs/DB00855
    ApprovedInvestigational

    A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]

    Categories: Sensitizers Used in Photodynamic/radiation Therapy
  10. Drug

    Varicella zoster vaccine (live/attenuated)

    go.drugbank.com/drugs/DB10318
    ApprovedInvestigational

    Since October 2017, however, it has been replaced as first line therapy by Shingrix ([DB13924]), a more effective and longer lasting vaccine[L1038]. … First approved in May 2006 by the Food and Drug Administration, Zostavax was the first vaccine available for the prevention of shingles.

    Mixtures: Priorix - Tetra Pulver in einer Durchstechflasche und Lösungsmittel in einer Fertigspritze zur Herstellung einer InjektionslösungProducts: Varilrix Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze, VARIVAX Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze